Pinja Ilmarinen, PhD, Leena E

Slides:

Advertisements

Similar presentations

내과 R2 이지영. INTRODUCTION  Asthma  Allergic airway inflammation,Th2-weighted process  Biomarkers  Phenotypic distinctions  Development of personalized.

Advertisements

Biologics in Asthma—The Next Step Toward Personalized Treatment

Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: A population-based study

Pinja Ilmarinen, PhD, Leena E

The Relationship Between a Specific IgE Level and Asthma Outcomes: Results from the National Health and Nutrition Examination Survey Whitney.

Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity Andrei Malinovschi,

Asthma Yardstick Annals of Allergy, Asthma & Immunology

Mental Health Services Claims and Adult Onset Asthma in Ontario, Canada Teresa To, PhD, Kandace Ryckman, MPH, Jingqin Zhu, MSc, Devon Williams, MSc, Laura.

Von Ta, MD, Andrew A. White, MD

Diagnostic Accuracy of Inflammatory Markers for Diagnosing Occupational Asthma Geneviève Racine, Roberto Castano, MD, PhD, André Cartier, MD, Catherine.

Advances in Diagnosing Peanut Allergy

Risk of an asthma exacerbation after bariatric surgery in adults

Could Fractional Exhaled Nitric Oxide Test be Useful in Predicting Inhaled Corticosteroid Responsiveness in Chronic Cough? A Systematic Review Woo-Jung.

Antonio Anzueto, MD, Marc Miravitlles, MD CHEST

Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma Willem M.C. van Aalderen, MD, PhD, Jonathan Grigg,

The ABCs of Asthma Control

The Role of the Primary Care Physician in Helping Adolescent and Adult Patients Improve Asthma Control Barbara P. Yawn, MD, MSc Mayo Clinic Proceedings

The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD

Rohit K. Katial, MD, Greg W. Bensch, MD, William W

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Long-Term Inhaled Corticosteroid Adherence in Asthma Patients with Short-Term Adherence Laurent Laforest, MD, PhD, Manon Belhassen, MSc, Gilles Devouassoux,

Volume 153, Issue 4, Pages (April 2018)

Volume 153, Issue 4, Pages (April 2018)

Asthma diagnosis and treatment: Filling in the information gaps

The prevalence of severe refractory asthma

Severe Asthma in Primary Care: Identification and Management

Jason S. Debley, MD, MPH, David C. Stamey, RRT, Elizabeth S

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Jennie Gane, MBChB (Hons), MSc, Roger Buckley, BM BCh, MA, FRCS

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Desensitization to Chemotherapeutic Agents

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Adult Asthma Scores—Development and Validation of Multivariable Scores to Identify Asthma in Surveys Ana Sá-Sousa, MSc, Ana Margarida Pereira, MD, Rute.

NAEPP Expert Panel Report

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Safety of Fluticasone Propionate Prescribed for Asthma During Pregnancy: A UK Population-Based Cohort Study Rachel A. Charlton, PhD, Julia M. Snowball,

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison William Busse, MD, Geoffrey Chupp,

The Relationship Between a Specific IgE Level and Asthma Outcomes: Results from the National Health and Nutrition Examination Survey Whitney.

Advances in Diagnosing Peanut Allergy

Nonadherence to Asthma Treatment: Getting Unstuck

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study Thomas B. Casale, MD, Allan.

Michael E. Wechsler, MD Mayo Clinic Proceedings

Thys van der Molen, MD, PhD, Monica Fletcher, MSc, David Price, FRCGP

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Necdet B. Gunsoy, PhD, Sarah M. Cockle, PhD, Steven W

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12- month follow-up analysis Pranabashis Haldar, MD, Christopher E. Brightling,

Pinja Ilmarinen, PhD, Leena E

The Management of Eosinophilic Esophagitis

Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study Bradley E.

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

Sharon Seth, MD, David A. Khan, MD

Biomarker-based asthma phenotypes of corticosteroid response

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Sophie F. Demarche, MPharm, Florence N. Schleich, MD, PhD, Virginie A

Therapeutic strategies to reduce asthma exacerbations

Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation Anthony P. Sampson, PhDa, Emilio Pizzichini, MD, PhDb,

Von Ta, MD, Andrew A. White, MD

The Journal of Allergy and Clinical Immunology: In Practice

Nitric oxide as a clinical guide for asthma management

Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children Georgette Stern, MSc, Johan de Jongste, MD, Ralf.

Larry C. Borish, MDa, Harold S

Budesonide Inhalation Suspension Versus Montelukast in Children Aged 2 to 4 Years with Mild Persistent Asthma Stanley J. Szefler, MD, Lars-Goran Carlsson,

Pedro Giavina-Bianchi, MD, PhD, Shih-Wen Huang, MD

News & Notes Journal of Allergy and Clinical Immunology

Caring for the smoking asthmatic patient

Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies Frank C. Albers, MD, PhD, Robert G. Price,

Presentation transcript:

Prevalence of Patients Eligible for Anti-IL-5 Treatment in a Cohort of Adult-Onset Asthma Pinja Ilmarinen, PhD, Leena E. Tuomisto, MD, PhD, Onni Niemelä, MD, PhD, Hannu Kankaanranta, MD, PhD The Journal of Allergy and Clinical Immunology: In Practice Volume 7, Issue 1, Pages 165-174.e4 (January 2019) DOI: 10.1016/j.jaip.2018.05.032 Copyright © 2019 The Authors Terms and Conditions

Figure 1 Prevalence of patients fulfilling different combinations of the clinical criteria related to eligibility to anti-IL-5 therapy in the cohort of adult-onset asthma (n = 203). A, Prevalence of patients fulfilling different criteria for the level of blood eosinophils or FeNO, exacerbations, and use of medication. B, Prevalence of patients fulfilling different criteria for the level of blood eosinophils (B-eos) or FeNO without the need to fulfill criteria for frequent exacerbations or use of medium-to-high ICS dose for asthma. FeNO, Fraction of exhaled nitric oxide; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, 165-174.e4DOI: (10.1016/j.jaip.2018.05.032) Copyright © 2019 The Authors Terms and Conditions

Figure 2 Prevalence of severe asthma (SA) in patients with adult-onset asthma. High-intensity medication refers to daily use of high ICS dose together with second controller (LABA, LTRA, or theophylline), or systemic steroid for at least 50% of the previous year. Definition of severe asthma includes the use of high-intensity medication and uncontrolled asthma as defined by ACT score <20, ≥2 exacerbations previous year, and/or prebronchodilator FEV1 <80% predicted. ACT, Asthma control test; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, 165-174.e4DOI: (10.1016/j.jaip.2018.05.032) Copyright © 2019 The Authors Terms and Conditions

Figure 3 A, Asthma-related visits to health care in patients with nonsevere asthma, severe asthma, and eligible for anti-IL-5 therapy. B, Planned visits include asthma-related follow-up visits. C, Unplanned visits include visits related to exacerbations and acute respiratory tract infections. Anti-IL-5 eligible patients refer to those who fulfill criteria for the primary endpoint of this study (daily use of medium-to-high ICS dose and LABA, ≥2 exacerbations per previous year, and blood eosinophil level ≥ 300 cells/μL or FeNO ≥ 50 ppb). FeNO, Fraction of exhaled nitric oxide; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, 165-174.e4DOI: (10.1016/j.jaip.2018.05.032) Copyright © 2019 The Authors Terms and Conditions

Figure 4 Prevalence of anti-IL-5 eligible asthma, severe asthma, and nonsevere asthma in cohort of adult-onset asthma (SAAS). One patient overlap existed in the groups of anti-IL-5 eligibility and severe asthma. CI, Confidence interval; SAAS, Seinäjoki Adult Asthma Study. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, 165-174.e4DOI: (10.1016/j.jaip.2018.05.032) Copyright © 2019 The Authors Terms and Conditions